Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Treatment of Bulimia Nervosa in a Primary Care Setting
- Conditions
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Treatment for Adolescents With Depression Study (TADS)
- Conditions
- First Posted Date
- 2000-09-15
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 432
- Registration Number
- NCT00006286
- Locations
- 🇺🇸
Behavioral Health Center, Charlotte, North Carolina, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Treatment of Depression in Youth With Bipolar Disorders
- Conditions
- First Posted Date
- 2000-04-03
- Last Posted Date
- 2005-11-21
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Registration Number
- NCT00005015
Fluoxetine for Anxious Children
- Conditions
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00000381
Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)
- Conditions
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Boston University
- Registration Number
- NCT00000379
- Locations
- 🇺🇸
The Trauma Center, Brookline, Massachusetts, United States
Study of Fluoxetine in Patients With Depersonalization Disorder
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 80
- Registration Number
- NCT00004446
- Locations
- 🇺🇸
Mount Sinai Medical Center, NY, New York, New York, United States
Randomized Study of Fluoxetine in Children and Adolescents With Autism
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 45
- Registration Number
- NCT00004486
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
🇺🇸New York University Medical Center, New York, New York, United States
IV Cocaine Abuse: A Laboratory Model - 2
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- New York State Psychiatric Institute
- Registration Number
- NCT00000213
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.